FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain 
Dollar Strengthens as U.S.-Iran Peace Talks Send Mixed Signals 
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
China Opens Door to Stronger U.S. Trade Ties Amid Rising Tensions 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Japan Eyes Oil Futures Intervention to Stabilize Yen Amid Middle East Crisis 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Gold Prices Drop Amid Iran Peace Talk Uncertainty and Stronger Dollar 
Researchers from the Korea Advanced Institute of Science and Technology (KAIST) have developed a wearable green organic light-emitting diode (OLED) with a 470-nanometer (nm) wavelength that can cure jaundice in infants.
The OLED provides sufficient power for jaundice treatment even at low voltage, durability for over 100 hours of operation, a low operating temperature of less than 35 Celsius degrees, and flexibility that can endure over 1,000 bends at a 2 mm radius of curvature.
The bilirubin level of the infants’ serum reaches 12 milligrams per decilitre (mg/dL) within three hours of being exposed to the OLED, indicating the completed treatment of jaundice.
Unlike existing light-emitting diode (LED)-based jaundice treatment devices currently used at hospitals, the OLED showed uniform and effective treatment functions.
